Chapter 7

Durable vs Cyclical

Over FY2021–FY2025 Vital Farms added roughly $498 million of net revenue — about 61% from volume and 39% from its own price increases [1] [2]. The cyclical slice the 2026 reset exposed is not a price windfall on Vital Farms' own shelf but a trial windfall: avian-flu-inflated commodity prices made trying the brand cheap, and in 2024–2025 more than 55% of buyers were brand-new households. As the premium re-widened, new-buyer share fell to 50%, and FY2026 revenue is guided to just +2% to +5% despite a record distribution year [3].

This chapter decomposes the growth the fallen-star-versus-value-trap question turns on: how much of the FY2021–FY2025 build was durable, and how much was a cheap-trial window that is now closing.

The four-year revenue bridge

The split between volume and price is disclosed each year in the 10-K, and it is volume that did most of the work. Across the four annual steps, volume contributed roughly $306 million and price/mix roughly $193 million of the ~$498 million added.

Source: FY2022–FY2025 10-Ks, Results of Operations [4]; [5]; [6]; [7].

Source: derived from FY2022–FY2025 10-K revenue-driver disclosures [8].

Two features matter for the durability question. First, the mix of drivers moved year to year rather than following commodity egg prices: FY2023 was the one price-led year (+$59.4 million price versus +$50.5 million volume, of which a 53rd week added $8.5 million) [9], while FY2024 — the peak avian-flu year — was three-quarters volume (+$103.0 million volume versus +$31.5 million price) [10]. If high commodity prices had simply inflated Vital Farms' own realized price, the price line would have swelled in 2024; instead volume did.

Second, the price/mix that did land came from Vital Farms' own list actions, not from riding the commodity spike. The FY2023 gross-margin bridge attributes the gain to "pricing increases across the entire shell egg portfolio in January 2023" [11], and FY2024 to "price increases on our organic egg portfolio in January 2024" plus fully realizing the February 2023 increase [12]. These are administered price moves that hold when commodity eggs cheapen — a different kind of durability than a spot-price windfall.

A trial windfall, not a price windfall

The cyclical exposure sits inside the volume line, through trial. Avian-flu outbreaks inflated conventional and, in turn, competing premium egg prices; that compressed Vital Farms' relative premium and lowered the cost of trying the brand for the first time. Management quantified the effect directly: in 2024 and 2025 more than 55% of its buyers were households that had not purchased Vital Farms before, and that new-buyer rate dropped to 50% in the first quarter of 2026 as price gaps widened again [13].

Source: Q1 FY2026 earnings call ("more than 55%" in 2024–25, "just 50%" in Q1 2026) [14].

The reversal runs through the same channel that the surge did. Management notes that where price gaps to outdoor-access competitors widened most, volume growth turned negative; where gaps stayed moderate, growth held. Narrowing the gap at one top-10 customer from about 35% to about 25% above competing premium eggs lifted volume 18% in two weeks [15]. The binding variable is Vital Farms' premium over other premium branded and private-label eggs, not over conventional eggs — a refinement of the price-gap mechanism the Category and Moat chapter first surfaced. That gap is set partly by competitors who followed commodity eggs down to multi-year lows in 2026, which is why the trial engine is cyclical and not fully in Vital Farms' hands.

The durable engine

The other engine is structural and still running. The clearest evidence is that the base did not crack when trial stalled: through the 2026 shock, existing households bought about 2% more per retained household than the prior eight-quarter average, and resisted trading down [16]. Vital Farms shell eggs reach roughly 10.5% of U.S. households against a category at 97.3%, so the penetration runway is set by awareness and distribution rather than by the price cycle [17].

The December 2025 investor day framed the durable-engine metrics against 2020, before the flu cycle: household penetration 11.9% (up 6.2 points), household retention 51% (up 5 points), aided brand awareness 33% (up 16 points), average items carried per retailer up 43%, shelf velocity up 68%, across 23,680 stores [18].

Source: December 2025 Investor Day, brand and retailer metrics versus 2020 [19].

Distribution is the piece of that engine most clearly independent of the price cycle, and it kept accelerating while velocity fell. Total distribution points averaged 115.8 in Q1 2025, 144.8 in Q4 2025 and 149.8 in Q1 2026, with management guiding to 170–175 by Q4 2026 — what it expects to be its single best yearly distribution gain since going public [20].

Source: Q1 FY2026 earnings call; 4Q26 is the midpoint of the 170–175 guide [21].

Sizing the unwind

The FY2026 guide measures how large the trial reversal is relative to the durable engine. Revenue is guided to $775–800 million, or +2% to +5% over FY2025's $759.4 million, including the record distribution year above [22]. Set against three prior years of 25%–39% growth, a low-single-digit result while distribution posts its best-ever gain implies the stalled trial-and-velocity engine is currently offsetting most of what a record distribution year would otherwise add.

Source: Q1 FY2026 earnings call guidance ($775–800M) against FY2025 actual [23].

Management's own plan is for the two engines to re-cross within the year: distribution gains take full effect in the back half, price-gap narrowing restores velocity, and revenue-generating volume growth turns positive in the third quarter and accelerates into the fourth [24]. That path is conditional: it assumes competing premium and breaker prices hold at current levels, a floor the company does not set — the same price-floor dependency the Unit Economics bridge rests on.

Balance of the evidence

The weight of the four-year record is durable. Most of the $498 million added was volume, the price/mix that landed was administered rather than commodity-driven, and the base-loyalty, penetration, retention and distribution metrics all built through and past the flu cycle. On that reading, the reset is a demand-mix event on an intact franchise, and the fallen-star framing fits better than the value-trap one.

The qualification is real and current. A visible share of 2024–2025's acceleration was cheap trial acquired while the premium was compressed, and that trial is reversing fast enough that, in 2026, it neutralizes even a record distribution year — with the decisive input, competitors' pricing, outside Vital Farms' control. The read would strengthen if new-buyer share climbs back toward the 55%-plus level as gaps narrow and revenue-generating volume turns positive in the second half; it would weaken if velocity stays negative in the wide-gap geographies and the distribution gains cannot carry the top line on their own.